Back to Archived Journals » Gastrointestinal Cancer: Targets and Therapy » Volume 6

Optimal management of venous thromboembolism in advanced pancreatic cancer with low-molecular-weight heparin: current evidence

Authors Perl G, Brenner B, Ben-Aharon I

Received 6 April 2016

Accepted for publication 14 June 2016

Published 31 October 2016 Volume 2016:6 Pages 49—54


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Eileen O'Reilly

Gali Perl,1,2 Baruch Brenner,1,2 Irit Ben-Aharon1,2

1Institute of Oncology, Davidoff Center, Rabin Medical Center, Beilinson Hospital Campus, Petah Tikva, 2Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel

Abstract: Former evidence delineates a strong correlation between cancer and venous thromboembolic events (VTEs). Of all the malignancies, pancreatic cancer confers the highest risk for developing VTE during the course of the disease. The role of primary thromboprophylaxis in the comprehensive treatment of pancreatic cancer remains unclear. We have conducted a systematic review to assess the role of primary thromboprophylaxis in pancreatic cancer. Literature searches included PUBMED, EMBASE, Cochrane Library, and the database of clinical trials in order to identify relevant publications. Seven publications that included 6,003 patients were analyzed in our systematic review. The systematic review of current literature indicates that thromboprophylaxis reduces the risk of VTE without increasing the risk of major bleeding. However, data regarding survival benefits are inconclusive.

Keywords: low-molecular-weight heparin, pancreatic cancer, thrombophylaxis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]